Alphabiome AI is a B2B microbiome analytics platform that applies artificial intelligence to analyze microbiome-derived DNA at large scale to identify biomarkers associated with treatment response and to license predictive models for precision medicine and drug development.
Published Jun 25, 2026
No public market share data were found in accessible sources.
| Starting Price | Not publicly disclosed | Not publicly disclosed | Not publicly disclosed |
| Primary Customers | Pharma/biotech seeking microbiome-driven treatment-response biomarkers; agrifood/livestock applications | Organizations pursuing microbiome-based therapeutics | Oncology/precision-medicine teams seeking integrated multi-omics reporting |
| Key Public Evidence | Reference-free analytics narrative and a peer-reviewed livestock validation | Microbiome therapeutics platform with in-house development capabilities | Clinical-report framing and pathway/evidence synthesis positioning |
| Key Weakness | Limited public third-party reviews; limited public enterprise compliance artifacts; limited published human clinical utility evidence | Not positioned as a direct biomarker licensing platform; varies by program | Not microbiome-specialized; may not address microbiome-specific analytics |
—